Bupropion
Bupropion, also sold as Wellbutrin or Zyban, is an antidepressant. It is also used to help people quit smoking.[1][2] Bupropion is different from other antidepressants because it does not often cause weight gain or sleepiness.[3] However, it has a higher chance of causing seizures than other antidepressants.
Common side effects of bupropion are having a dry mouth, nausea, lack of sleep, a lot of sweating, anxiety and constipation (difficulty pooping).[4] It can also increase blood pressure.[5] Using bupropion while pregnant can give the baby congenital heart defects.
Bupropion was made by Nariman Mehta in 1969. It was first used in the United States in 1985. Bupropion was first called amfebutamone, but it was renamed in 2000.[6] In 2020, it had more than 25 million prescriptions in the United States.[7]
References[change | change source]
- ↑ "Bupropion hydrochloride (Zyban) for quitting smoking". Webmd.com. 2009-07-22. Retrieved 2011-11-04.
- ↑ Patel, Krisna; Allen, Sophie; Haque, Mariam N.; Angelescu, Ilinca; Baumeister, David; Tracy, Derek K. (April 6, 2016). "Bupropion: a systematic review and meta-analysis of effectiveness as an antidepressant". Therapeutic Advances in Psychopharmacology. 6 (2): 99–144. doi:10.1177/2045125316629071. ISSN 2045-1253. PMC 4837968. PMID 27141292.
- ↑ Dhillon, Sohita; Yang, Lily P. H.; Curran, Monique P. (2008). "Bupropion: a review of its use in the management of major depressive disorder". Drugs. 68 (5): 653–689. doi:10.2165/00003495-200868050-00011. ISSN 0012-6667. PMID 18370448.
- ↑ (PDF). 2011-07-17 https://web.archive.org/web/20110717003144/http://us.gsk.com/products/assets/us_wellbutrinXL.pdf. Archived from the original (PDF) on 2011-07-17. Retrieved 2022-11-17.
{{cite web}}: Missing or empty|title=(help) - ↑ Wilens, Timothy E.; Hammerness, Paul G.; Biederman, Joseph; Kwon, Anne; Spencer, Thomas J.; Clark, Sarah; Scott, Megan; Podolski, Amy; Ditterline, Jeffrey W.; Morris, Matthew C.; Moore, Hadley (February 2005). "Blood pressure changes associated with medication treatment of adults with attention-deficit/hyperactivity disorder". The Journal of Clinical Psychiatry. 66 (2): 253–259. doi:10.4088/jcp.v66n0215. ISSN 0160-6689. PMID 15705013.
- ↑ "International nonproprietary names for pharmaceutical substances (INN) : proposed international nonproprietary names : list 83 = Dénominations communes internationales des substances pharmaceutiques (DCI) : dénominations communes internationales proposées : liste 83 = Denominaciones comunes internacionales para las sustancias farmacéuticas (DCI) : denominaciones comunes internacionales propuestas : lista 83". WHO Drug Information 2000 ; 14(2) : 107-143. 2000. hdl:10665/58135.
- ↑ "The Top 300 of 2020". clincalc.com. Retrieved 2022-11-17.
